2025 North America Cell Viability Assays Market Revenue Opportunities Report
Description
The 2025 North America Cell Viability Assays Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Cell Viability Assays Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the North American Cell Viability Assays Market are Thermo Fisher Scientific, Merck KGaA (MilliporeSigma), Bio-Rad Laboratories, and PerkinElmer Inc. Thermo Fisher Scientific leads with a strong presence offering products like AlamarBlue and automated cell counters, boasting a market cap of approximately $220 billion. Merck operates in the region as MilliporeSigma, providing CellTiter-Glo and other assay kits, with a market cap near $90 billion. Bio-Rad supplies Trypan Blue dye exclusion kits and automated cell counters, while PerkinElmer focuses on precision instruments such as multilabel plate readers, with market caps around $18 billion and $17 billion respectively.
These companies dominate the North American market, which holds about 40% of the global revenue share due to high-quality infrastructure and significant cancer research funding in the U.S. The market benefits from increasing chronic disease incidences and government investments. Product segments leading the market include reagents and kits, which represent around 65% of sales. The U.S. specifically accounts for a large share, projected to grow at a CAGR of 9.9% through 2030, supported by rising adoption of cancer therapies and growing research collaborations such as Promega and FUJIFILM Cellular Dynamics for novel assay development.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Cell Viability Assays Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the North American Cell Viability Assays Market are Thermo Fisher Scientific, Merck KGaA (MilliporeSigma), Bio-Rad Laboratories, and PerkinElmer Inc. Thermo Fisher Scientific leads with a strong presence offering products like AlamarBlue and automated cell counters, boasting a market cap of approximately $220 billion. Merck operates in the region as MilliporeSigma, providing CellTiter-Glo and other assay kits, with a market cap near $90 billion. Bio-Rad supplies Trypan Blue dye exclusion kits and automated cell counters, while PerkinElmer focuses on precision instruments such as multilabel plate readers, with market caps around $18 billion and $17 billion respectively.
These companies dominate the North American market, which holds about 40% of the global revenue share due to high-quality infrastructure and significant cancer research funding in the U.S. The market benefits from increasing chronic disease incidences and government investments. Product segments leading the market include reagents and kits, which represent around 65% of sales. The U.S. specifically accounts for a large share, projected to grow at a CAGR of 9.9% through 2030, supported by rising adoption of cancer therapies and growing research collaborations such as Promega and FUJIFILM Cellular Dynamics for novel assay development.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
